Skip to content

You are about to review presentations, reports, filings and/or other materials regarding Amarin Corporation plc (NASDAQ: AMRN) that contain time-sensitive information. The information contained therein is only current as of the date thereof and may not be a complete listing of all documents filed with the Securities Exchange Commission, made public or provided to Amarin shareholders.

 

Amarin expressly disclaims any obligation to review, update or correct these materials after the date thereof. Amarin may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.

 

Certain statements made on this web site or in materials accessed in or through the investor relations section of our web site are "forward-looking statements," which are subject to risks and uncertainties, and Amarin's actual results may differ (possibly materially) from those indicated in such statements. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q.

 

This website is not an offer or a solicitation to buy or sell securities. Please be aware that decisions regarding investments are the responsibility of users. Although this website includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice.

 

This information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates.

 

Information on this website may be revised without any prior notice.

Investor Relations / Investor FAQs

Investor FAQs

Please click here for a fact sheet on VASCEPA and a glossary of related terms.

Show All
Have the briefing documents been published for the November 14, 2019 FDA Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meeting...

Please click here.

What is Amarin’s perspective on the October 29th summary judgment ruling in the ongoing Vascepa® ANDA litigation?

Please click here.

Will increased demand for Vascepa® negatively affect the global fish supply?
Please click here. 
What medical societies have recognized REDUCE-IT™ in their guidelines or scientific statements?

Please click here.

What is the PDUFA goal date assigned by the FDA for the expanded indication Amarin is seeking for Vascepa® based on the REDUCE-IT™ cardiovascular outcomes trial?

Please click here.

Has the FDA confirmed November 14, 2019 as the date for the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meeting to review Amarin’s supplemental new drug application related to the REDUCE-IT cardiovascular outcomes trial?

Please click here.

What is Amarin’s position on The Institute for Clinical and Economic Review (ICER) draft evidence report regarding the cost effectiveness and value of Vascepa®?
Please click here. 
Where can I find the New England Journal of Medicine (NEJM) publication of the primary results of the REDUCE-IT® cardiovascular outcomes study?

The primary results of the REDUCE-IT cardiovascular outcomes study, which demonstrated that Vascepa® significantly lowers the rate of occurrence of major adverse cardiovascular events in at-risk patients, was published and can be found at: https://investor.amarincorp.com/publications under the Cardiovascular Outcomes Trials heading.

The results of the Total Events Analysis of the REDUCE-IT cardiovascular outcomes study published in the Journal of American College of Cardiology (JACC) is also available in the above section.

Other publications pertaining to Vascepa and the science supporting Vascepa are available at: https://investor.amarincorp.com/publications.

What type of medical education is provided regarding REDUCE-IT® results?

Commencing with the initial presentation of the REDUCE-IT™ results as late breaking clinical results at the American Heart Association’s 2018 scientific sessions on November 10, 2018, Amarin has sponsored numerous presentations regarding the landmark results of the REDUCE-IT study. These include multiple, independently organized, continuing medical education (CME) programs. While organizers of CME programs often do not make their entire publications public, the following is a link to the publicly available portion of the CME program that was conducted in November 2018, organized by Medtelligence, and made public by ReachMD: https://reachmd.com/programs/cme/new-options-to-reduce-cardiovascular-events-in-atherosclerotic-cardiovascular-disease-ascvd/10494/

Why has an outcomes study not been conducted for patients with TG levels ≥500 mg/dL?
Please click here. 
How does Vascepa work in lowering cardiovascular risk (Updated April 18, 2019)?
Please click here
What is the difference between using TG levels as an identifier of CV risk and correlating lowering TG levels and lowering CV risk?
Please click here.
What is Amarin’s perspective on the potential for competitors to use changes in biomarkers demonstrated in clinical trials of Vascepa®, such as triglyceride level reduction, as a regulatory substitute for completing their own CVOT?
Please click here.
What is the clinical need and scientific rationale for the REDUCE-IT study (Updated March 19, 2019)?

Please click here.

What is Amarin’s perspective on the use of mineral oil in its clinical trials and the variability commonly observed in blood-based lipid values in clinical trials of statin-stabilized patients (updated November 23, 2018)?

Please click here.

I heard the Global Principal Investigator for the REDUCE-IT study comment in his late-breaker presentation at AHA that there was no change in hsCRP in the placebo-arm of the study, please explain why that was referenced?

Please click here.

What is Amarin’s perspective on the editorial in NEJM commenting on the primary publication of REDUCE-IT results in NEJM (Bhatt et al. 2018)?
Please click here
What are Amarin’s plans and timing for Vascepa® in Europe?

Please click here.

What is Amarin’s opinion on the VITAL clinical trial?

Please click here.

What is Amarin’s opinion on the ASCEND clinical trial?

Please click here.

What is Amarin’s view on the June 19, 2019 CFSAN evaluation of proposed qualified health claims applicable to food and dietary supplement products containing the omega-3 acids?
Please click here.
Where can I find the approved label for Vascepa?

See www.vascepa.com

What is Amarin’s view on the reliability of third-party script reporting services?
Please click here.
How can I keep up to date with latest developments at Amarin?

You can register to receive updates announced by Amarin by submitting your email address on the Email Alerts section of our website, which option can be found on each page of the website www.amarincorp.com.

What is Amarin's perspective on the results of Novartis' CANTOS study on canakinumab (Updated March 19, 2019)

Please see the attached document for a detailed response. This information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates. Click Here.

What is Amarin’s perspective regarding the complete response letter that Novartis received regarding its drug canakinumab as a potential treatment for cardiovascular risk reduction?

Please click here

What does Amarin think about the JAMA and Cochrane omega-3 meta-analyses?

Please click here.

What patents are most relevant to the ongoing ANDA litigation?

Please click here.

Where can I get a copy of the August 2015 First Amendment opinion and March 2016 settlement resulting from the May 2015 lawsuit filed by Amarin and a group of independent physicians?
For opinion click here
For settlement click here 
What is Amarin doing to protect the Vascepa® franchise against dietary supplement manufacturers that mislead the public by referencing REDUCE-IT™ or Vascepa®? (updated May 7, 2019)
Please click here.
What is the status of the ITC lawsuit Amarin filed in August 2017 to prevent the import and sale into the United States of synthetic omega-3 products that are comprised predominantly of EPA and sold for use in, or as, dietary supplements?
Please click here
What is Amarin’s policy on market rumors, speculation and related stock price movements?
Amarin has a general policy to not comment on rumors or speculation, or stock price movement related to such rumors or speculation. A “no comment” comment from Amarin is neither confirmation nor denial of any given rumor or speculation; it simply relays that Amarin has no comment on the matter.
Is Amarin subject to the UK City Code on Takeovers and Mergers?

Amarin Corporation plc is not subject to the UK City Code on Takeovers and Mergers (the “Code”) because the central management and control of Amarin is situated outside the UK. Amarin is therefore not subject to Code requirements, including but not limited to, press release requirements if, under certain circumstances, the company is “the subject of rumour or speculation” or there is an “untoward movement” in the target share price.

Amarin is subject to the UK Companies Act 2016 as a company organized under the law of England and Wales. For more information, please review the public disclosures in our most recent 10-K, page 67-68: https://www.sec.gov/Archives/edgar/data/897448/000119312517065969/d328533d10k.htm.

Despite being a company organized under such law, Amarin has an Irish, and not UK, tax residency for its parent company and for its wholly-owned subsidiary within which Vascepa revenues are recorded.

On what stock exchanges are Amarin's ordinary shares traded?

Amarin's ordinary shares, represented by American Depositary Shares, are listed on the NASDAQ Capital Market under the ticker AMRN.

Until July 16th 2008, Amarin's ordinary shares were also listed on London's AIM (ticker: AMRN) and Dublin's IEX (ticker: H2E).

What is an ADS/ADR?

    An American Depositary Share (ADS) is a security that represents an ownership interest in the shares of a foreign company trading on a U.S. securities market. The shares represented by the ADSs are held by a U.S. depositary bank and are evidenced by certificates called American Depositary Receipts (ADRs), although the terms ADS and ADR are often used interchangeably. ADRs enable U.S. investors to buy shares in foreign companies without undertaking cross-border transactions (i.e., in U.S. dollars), and they trade, clear and settle in accordance with U.S. market regulations and conventions.

What types of companies issue ADRs?

Non-U.S. companies whose securities trade on a U.S. securities market.

What is the ratio of Amarin ADRs to Amarin ordinary shares?

One Amarin ADR equals one Amarin ordinary share.

Are holders of ADRs entitled to vote at Amarin's annual general meeting?

Holders of ADRs may authorize Citibank, Amarin's Depositary, to act as a proxy in exercising voting rights according to the number of ordinary shares represented by their respective ADRs.

When is Amarin's fiscal year?

Amarin's fiscal year is the 12-month calendar year ending December 31st.
 

Where can I get information on the company?

Please visit our website at www.amarincorp.com where you can read more on our executive team, board of directors, company strategy, corporate governance, therapeutic focus, product pipeline and partnering activities.

Where are Amarin's headquarters?

Amarin is headquartered in Dublin, Ireland.

Where can I find Amarin's financial statements?

Amarin's financial statements, including annual reports, can be found on Amarin's website www.amarincorp.com in the Investor Relations section here. Alternatively, you can find all of Amarin's filings with the U.S. Securities and Exchange Commission under the SEC Filings section of the website here.

Who is Amarin's Registrar/Transfer Agent?

The U.S. Transfer Agent for Amarin's ADS holders is:

Citibank Shareholder Services
P.O. Box 43077
Providence, RI 02940-5000
USA
Tel: +1-877-248-4237d

The Registrar for Amarin's ordinary shares is:

Citi - Depositary Receipt Services
388 Greenwich Street
14th Floor
New York, NY 10013

AND

Equiniti
PO Box 4630,
Aspect House,
Spencer Road,
Lancing, West Sussex,
BN99 6QQ, England
Telephone: +44 121 415 7047d

Who is Amarin's Depositary?

The Depositary for Amarin's ADRs is:

Citibank Shareholder Services
P.O. Box 43077
Providence, RI 02940-5000
Tel: +1-877-248-4237d Fax: +1-201-324-3284d

citibank@shareholders-online.com

Who is Amarin's independent registered public accounting firm?

Ernst & Young LLP

99 Wood Avenue South

Iselin, NJ 08830

Who can I contact regarding Amarin investor and shareholder related queries?

Please contact: Elisabeth Schwartz
Telephone (U.S.): 908-719-1315d
e-mail: investor.relations@amarincorp.com
 

Amarin Corporation